Jun 30, 2025 7:52 pm EDT Achieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters’ Option to Purchase Additional Securities
Jun 26, 2025 11:43 pm EDT Achieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public Offering
Jun 26, 2025 4:02 pm EDT Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades
Jun 26, 2025 4:01 pm EDT Achieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking Cessation
May 28, 2025 8:30 am EDT Achieve Life Sciences to Present at the Jefferies Global Healthcare Conference
May 20, 2025 8:30 am EDT Achieve Life Sciences to Present New Data at the 2025 ATS International Conference Demonstrating that Cytisinicline Reduced Cravings and Nicotine Intake
May 13, 2025 7:30 am EDT Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program
May 6, 2025 8:30 am EDT Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025
Apr 21, 2025 11:19 am EDT Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine